• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics advances in efforts to get CMS to cover prescription digital therapeutics

February 28, 2022 By Sean Whooley

Pear TherapeuticsPear Therapeutics (NSDQ:PEAR) announced that the Centers for Medicare & Medicaid Services (CMS) established new coding relevant to its prescription digital therapeutics (PDTs).

CMS established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe prescription digital behavioral therapy — FDA-cleared — per course of treatment, which extends to PDTs including Pear’s reSET, reSET-O and Somryst.

Boston-based Pear’s offerings are the only FDA-authorized PDTs for treating substance use disorder (reSET), opioid use disorder (reSET-O) and chronic insomnia (Somryst), according to a news release.

The CMS coding decision, published on Feb. 16, 2022, becomes effective on April 1, 2022. The code for prescription digital behavioral therapy is “A9291.”

Pear Therapeutics designed its PDTs for collecting real-world data for use by prescribing clinicians and for population health management by payors and health systems. The PDTs use software to directly treat disease.

“We thank CMS for their decision to establish a new HCPCS code to describe prescription digital therapeutics and facilitate options for payers to provide access to these treatment options in response to Pear’s application,” Pear Therapeutics President and CEO Corey McCann said in the release. “This is an important reimbursement milestone for healthcare providers, payers and patients, and marks another step towards standard of care for coverage and payment for the PDT category.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance, Technology Tagged With: Pear Therapeutics

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS